Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for ...

More information: Bharti Garg et al, MICAL2 Promotes Pancreatic Cancer Growth and Metastasis, Cancer Research (2025). DOI: 10.1158/0008-5472.CAN-24-0744 Journal information: Cancer Research ...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study. Pancreatic cancer kills 50,000 people each year, according to ...

Telotristat ethyl to promote weight stability in patients with advanced pancreatic cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does ...

AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition ...

Today the American Cancer Society called out the need for more progress on pancreatic cancer, citing it as the third-leading cause of cancer-related death in the U.S. Their annual report also includes ...

Pancreatic cancer five-year relative survival: 12.8% Pancreatic cancer has a 12.8% five-year survival rate. It can be effectively treated if detected early, but when diagnosed at more advanced ...